ATE351916T1 - Lentivirale triplex-dns, und vektoren und rekombinante zellen, die lentivirale triplex-dns enthalten - Google Patents

Lentivirale triplex-dns, und vektoren und rekombinante zellen, die lentivirale triplex-dns enthalten

Info

Publication number
ATE351916T1
ATE351916T1 AT00969534T AT00969534T ATE351916T1 AT E351916 T1 ATE351916 T1 AT E351916T1 AT 00969534 T AT00969534 T AT 00969534T AT 00969534 T AT00969534 T AT 00969534T AT E351916 T1 ATE351916 T1 AT E351916T1
Authority
AT
Austria
Prior art keywords
recombinant cells
hiv
triplex dna
dna
vectors
Prior art date
Application number
AT00969534T
Other languages
English (en)
Inventor
Pierre Charneau
Veronique Zennou
Francoise Pflumio
Aude Sirven
Kupperschmitt Anne Dubart
Original Assignee
Pasteur Institut
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Inst Nat Sante Rech Med filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE351916T1 publication Critical patent/ATE351916T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT00969534T 1999-10-12 2000-10-10 Lentivirale triplex-dns, und vektoren und rekombinante zellen, die lentivirale triplex-dns enthalten ATE351916T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15838799P 1999-10-12 1999-10-12

Publications (1)

Publication Number Publication Date
ATE351916T1 true ATE351916T1 (de) 2007-02-15

Family

ID=22567880

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00969534T ATE351916T1 (de) 1999-10-12 2000-10-10 Lentivirale triplex-dns, und vektoren und rekombinante zellen, die lentivirale triplex-dns enthalten
AT07000486T ATE531808T1 (de) 1999-10-12 2000-10-10 Lentivirale triplex-dna und vektoren sowie rekombinante zellen mit lentiviraler triplex-dna

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07000486T ATE531808T1 (de) 1999-10-12 2000-10-10 Lentivirale triplex-dna und vektoren sowie rekombinante zellen mit lentiviraler triplex-dna

Country Status (15)

Country Link
US (7) US8093042B2 (de)
EP (2) EP1792997B1 (de)
JP (1) JP4436024B2 (de)
CN (2) CN100425702C (de)
AT (2) ATE351916T1 (de)
AU (2) AU784910B2 (de)
CA (1) CA2382832C (de)
CY (2) CY1106513T1 (de)
DE (1) DE60033045T2 (de)
DK (2) DK1792997T3 (de)
ES (2) ES2377721T3 (de)
HK (1) HK1050210B (de)
IL (3) IL148900A0 (de)
PT (2) PT1224314E (de)
WO (1) WO2001027304A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
DE69941703D1 (de) 1999-10-11 2010-01-07 Pasteur Institut Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen
HK1050210B (en) 1999-10-12 2007-08-24 Institut Pasteur Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
ATE527347T1 (de) 2001-08-02 2011-10-15 Inst Clayton De La Rech Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen
RU2305708C2 (ru) 2001-10-02 2007-09-10 Энститю Клейтон Де Ля Решерш Рекомбинантный лентивирусный вектор, клетка-хозяин, трансдуцированная лентивирусным вектором, способ ее трансдукции и применение
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
FR2872170B1 (fr) 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
US8222029B2 (en) * 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
EP1748067A1 (de) 2005-07-29 2007-01-31 Institut Pasteur Polynukleotide, die für MHC Klasse I-beschränkte Epitope der hTERT, Analoge und Polyepitope kodieren
ES2423518T3 (es) 2006-12-22 2013-09-20 Institut Pasteur Células y metodología para generar virus de ARN de cadena de sentido negativo no segmentada
WO2008134879A1 (en) 2007-05-04 2008-11-13 University Health Network Il-12 immunotherapy for cancer
EP2385107B1 (de) 2010-05-03 2016-08-24 Institut Pasteur Auf Lentivirusvektor basierende immunologische Verbindungen gegen Malaria
EP2666477A1 (de) 2012-05-23 2013-11-27 Theravectys Lentivirale Vektoren mit einem MHC-Klasse-I-Promotor
WO2012069657A1 (en) 2010-11-26 2012-05-31 Institut Pasteur Identification of a human gyrovirus and applications.
ES2651922T3 (es) 2011-11-08 2018-01-30 Institut Pasteur Polipéptidos de afinidad elevada para MAST2 y usos de los mismos
WO2013083753A2 (en) 2011-12-07 2013-06-13 Institut Pasteur Identification of a swine parecho-like virus and applications
WO2014016383A2 (en) 2012-07-25 2014-01-30 Theravectys Glycoproteins for pseudotyping lentivectors
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
EP3060670B1 (de) * 2013-10-24 2019-07-10 Ospedale San Raffaele S.r.l. Verfahren
EP3031923A1 (de) 2014-12-11 2016-06-15 Institut Pasteur Lentivirale, vektorbasierte immunogene Zusammensetzung gegen Japanische Enzephalitis
WO2016128549A1 (en) 2015-02-13 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides for engineering integrase chimeric proteins and their use in gene therapy
EP3380605A1 (de) 2015-11-24 2018-10-03 GlaxoSmithKline Intellectual Property Development Limited Transientes transfektionsverfahren zur retroviralen herstellung
EP3211003A1 (de) 2016-02-24 2017-08-30 Institut Pasteur T-zell-rezeptoren aus dem hiv-spezifischen repertoire, mittel zu deren herstellung und therapeutische verwendung davon
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
HUE055862T2 (hu) 2016-04-20 2021-12-28 Centro De Investig Energeticas Készítmények és eljárások PKLR fokozott génexpressziójára
KR102680200B1 (ko) * 2016-06-22 2024-07-02 예일 유니버시티 식물 의약을 위한 메커니즘 기반 품질 관리
EP3357506A1 (de) 2017-02-02 2018-08-08 Institut Pasteur Mehrere malaria-prä-erythrozyten-antigene und deren verwendung bei der auslösung einer schützenden immunantwort in einem wirt
EP3357504A1 (de) 2017-02-02 2018-08-08 Institut Pasteur Funktionelles screening von antigenen polypeptiden verwendung zur identifizierung von antigenen zur anregung einer schützenden immunantwort und zur auswahl von antigenen mit optimaler schutzwirkung
EP3592853A1 (de) 2017-03-09 2020-01-15 President and Fellows of Harvard College Unterdrückung von schmerzen durch geneditierung
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
SG11202002263TA (en) 2017-10-16 2020-04-29 Centro De Investigaciones Energeticas Medioambientales Y Tecnologicas Lentiviral vectors for delivery of pklr to treat pyruvate kinase deficiency
WO2019200167A1 (en) 2018-04-11 2019-10-17 Rocket Pharmaceuticals, Ltd. Compositions and methods for stem cell transplant
CA3096458A1 (en) 2018-04-12 2019-10-17 Umoja Biopharma, Inc. Viral vectors and packaging cell lines
MX2020011386A (es) 2018-04-27 2021-01-29 Spacecraft Seven Llc Terapia genica para la degeneracion del snc.
WO2019226650A1 (en) 2018-05-23 2019-11-28 Modernatx, Inc. Delivery of dna
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
US20220017920A1 (en) 2018-11-21 2022-01-20 Umoja Biopharma, Inc. Multicistronic vector for surface engineering lentiviral particles
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191233A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2020252455A1 (en) 2019-06-13 2020-12-17 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
CA3154281A1 (en) 2019-10-16 2021-04-22 Andrew Scharenberg Retroviral vector for universal receptor therapy
CN117120085A (zh) 2020-07-15 2023-11-24 巴斯德研究所 Sars-cov-2免疫原性组合物、疫苗和方法
WO2022015955A1 (en) 2020-07-16 2022-01-20 Umoja Biopharma, Inc. Gated adapter targeting receptor
CA3189601A1 (en) 2020-07-24 2022-01-27 The General Hospital Corporation Enhanced virus-like particles and methods of use thereof for delivery to cells
KR20230043869A (ko) 2020-08-07 2023-03-31 스페이스크래프트 세븐, 엘엘씨 Aav 벡터를 사용한 플라코필린-2(pkp2) 유전자 요법
WO2022058621A1 (en) 2020-09-21 2022-03-24 Theravectys High throughput methods and products for sars-cov-2 sero-neutralization assay
EP3984548A1 (de) 2020-10-16 2022-04-20 Institut Pasteur Generation von lentiviralen vektoren, die es ermöglichen, antigene zum mhc-ii-weg zu leiten und cd4+- und cd8+-t-zellantworten als immunantwort in einem wirt zu induzieren
EP4247963A1 (de) 2020-11-20 2023-09-27 Umoja Biopharma, Inc. Vektorsystem zur freisetzung mehrerer polynukleotide und verwendungen davon
US20250319173A1 (en) 2021-03-12 2025-10-16 Institut Pasteur Lentiviral vectors targeting antigens to mhc-ii pathway and inducing protective cd8+ and cd4+ t-cell immunity in a host
MX2024007261A (es) 2021-12-17 2024-08-06 Umoja Biopharma Inc Celula linfoide innata citotoxica y usos de la misma.
WO2023225569A1 (en) 2022-05-17 2023-11-23 Umoja Biopharma, Inc. Manufacturing viral particles
AU2023283552A1 (en) 2022-06-10 2025-01-23 Umoja Biopharma, Inc. Engineered stem cells and uses thereof
CN115358393B (zh) * 2022-09-13 2025-12-02 大连大学 一种基于相互作用力的dna三链体编码优化方法
EP4604993A2 (de) 2022-10-21 2025-08-27 Institut Pasteur Nichtstrukturelle flavivirus-antigene exprimierende polynukleotide und lentivirale vektoren aus der gruppe von denv, zikv und yfv, die schützende cd8+-t-zellimmunität in einem wirt induzieren
TW202434621A (zh) 2022-11-04 2024-09-01 美商優莫佳生物製藥有限公司 多核苷酸構築體及相關病毒載體及方法
WO2025129084A1 (en) 2023-12-13 2025-06-19 Umoja Biopharma, Inc. Engineered induced stem cell derived myeloid cells and methods of differentiating and using same
WO2025231174A1 (en) 2024-04-30 2025-11-06 Umoja Biopharma, Inc. Manufacturing viral particles

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
CA2247091A1 (en) * 1996-03-05 1997-09-12 The Regents Of The University Of California Recombinant live feline immunodeficiency virus and proviral dna vaccines
US20010007659A1 (en) 1997-04-17 2001-07-12 The University Of California Use of lentiviral vectors for antigen presentation in dendritic cells
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
US7622300B2 (en) 1998-06-03 2009-11-24 Kappes John C Trans-lentiviral vector particles and transduction of eukaryotic cells therewith
GB9825524D0 (en) * 1998-11-20 1999-01-13 Oxford Biomedica Ltd Vector
DE69941703D1 (de) 1999-10-11 2010-01-07 Pasteur Institut Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen
HK1050210B (en) 1999-10-12 2007-08-24 Institut Pasteur Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
US20030194392A1 (en) 2002-04-10 2003-10-16 Pierre Charneau Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US8222029B2 (en) 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
US8158413B2 (en) 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine

Also Published As

Publication number Publication date
IL198076A (en) 2011-12-29
CN1402793A (zh) 2003-03-12
US20180346928A1 (en) 2018-12-06
US20070224679A1 (en) 2007-09-27
US20150191745A1 (en) 2015-07-09
EP1224314B1 (de) 2007-01-17
CN101363029B (zh) 2016-01-13
HK1050210B (en) 2007-08-24
CA2382832C (en) 2012-06-26
US20120122963A1 (en) 2012-05-17
US9238824B2 (en) 2016-01-19
CY1106513T1 (el) 2012-01-25
HK1109167A1 (en) 2008-05-30
JP4436024B2 (ja) 2010-03-24
US20150011006A1 (en) 2015-01-08
EP1224314A2 (de) 2002-07-24
PT1224314E (pt) 2007-04-30
AU2006233199A1 (en) 2006-11-23
CN100425702C (zh) 2008-10-15
DE60033045T2 (de) 2007-11-08
AU7921700A (en) 2001-04-23
US8512994B2 (en) 2013-08-20
IL148900A (en) 2009-11-18
PT1792997E (pt) 2012-02-02
AU784910B2 (en) 2006-07-27
JP2003511083A (ja) 2003-03-25
HK1050210A1 (en) 2003-06-13
CY1112430T1 (el) 2015-12-09
US10407695B2 (en) 2019-09-10
DK1792997T3 (da) 2012-01-30
AU2006233199B2 (en) 2009-07-23
ATE531808T1 (de) 2011-11-15
US20120122204A1 (en) 2012-05-17
IL148900A0 (en) 2002-09-12
WO2001027304A3 (en) 2001-11-29
WO2001027304A2 (en) 2001-04-19
US8093042B2 (en) 2012-01-10
ES2280250T3 (es) 2007-09-16
DK1224314T3 (da) 2007-05-21
EP1792997A1 (de) 2007-06-06
ES2377721T3 (es) 2012-03-30
EP1792997B1 (de) 2011-11-02
DE60033045D1 (de) 2007-03-08
US8512993B2 (en) 2013-08-20
CN101363029A (zh) 2009-02-11
US20190119699A1 (en) 2019-04-25
CA2382832A1 (en) 2001-04-19

Similar Documents

Publication Publication Date Title
ATE351916T1 (de) Lentivirale triplex-dns, und vektoren und rekombinante zellen, die lentivirale triplex-dns enthalten
JP2020100622A5 (de)
DE69230993D1 (de) Rekombinante viren vektoren zur expression in muskelzellen
BR9914643A (pt) Vetores adeno-associados para expressão dofator viii por células alvo
PT2302063T (pt) Minicélulas intactas, como vetores para a transferência de adn e terapêutica genética in vitro e in vivo
WO2002014358A3 (en) Novel secreted proteins and their uses
CA2513072A1 (en) Cellular delivery and activation polypeptide-nucleic acid complexes
ATE293169T1 (de) Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen
WO2002008277A3 (en) Nucleic acids, vectors, host cells, polypeptides, and uses thereof
ATE293171T1 (de) Retrovirale, mit lcmv-glykoprotein pseudotypisierte hybrid-vektoren
DE60044754D1 (de) Trans-lentivirales Vektor System
ATE365807T1 (de) Hepatitis b virus vektoren für gentherapie
NO885090L (no) Polypeptider.
MXPA04004561A (es) Distribuidor de aire para sistema de biolixiviacion.
DK0651806T3 (da) Vacciner imod katteimmundeficiensvirus (FIV)
FR2600079B1 (fr) Vecteur viral et adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la proteine, proteine obtenue, vaccin et anticorps obtenus
DE3789545D1 (de) Impfstoff bestehend aus einem Virusvektor und Rekombinanten-DNS, die das p25-Protein vom AIDS-Virus kodieren.
WO2002012475A3 (en) C1q-related factor, homologous polypeptides and therapeutic uses thereof
Tay et al. Recent advances in mammalian cell transfection techniques
WO2024150828A1 (ja) 遺伝子導入方法
RU2227161C1 (ru) Рекомбинантная плазмидная днк рвмс-qp120(a)m-1 для иммунизации против вируса иммунодефицита человека
JP2024099482A (ja) 分子導入方法、分子導入効率改善剤、使用、分子導入細胞、分子導入細胞の製造方法、及び分子導入装置
JP2023534968A5 (de)
RU2346044C2 (ru) ЭКСПРЕССИОННАЯ ПЛАЗМИДНАЯ ДНК pBMC-gp140(A)-hum
WO2000053789A3 (de) Retrovirale expressionsvektoren auf der basis von herv-ltr-sequenzen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1224314

Country of ref document: EP